Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19 : A Systematic Review, Meta-Analysis, and Meta-Regression Analysis

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America..

The coronavirus disease 2019 (COVID-19) pandemic spread globally in the beginning of 2020. At present, predictors of severe disease and the efficacy of different treatments are not well understood. We conducted a systematic review and meta-analysis of all published studies up to 15 March 2020, which reported COVID-19 clinical features and/or treatment outcomes. Forty-five studies reporting 4203 patients were included. Pooled rates of intensive care unit (ICU) admission, mortality, and acute respiratory distress syndrome (ARDS) were 10.9%, 4.3%, and 18.4%, respectively. On meta-regression, ICU admission was predicted by increased leukocyte count (P < .0001), alanine aminotransferase (P = .024), and aspartate transaminase (P = .0040); elevated lactate dehydrogenase (LDH) (P < .0001); and increased procalcitonin (P < .0001). ARDS was predicted by elevated LDH (P < .0001), while mortality was predicted by increased leukocyte count (P = .0005) and elevated LDH (P < .0001). Treatment with lopinavir-ritonavir showed no significant benefit in mortality and ARDS rates. Corticosteroids were associated with a higher rate of ARDS (P = .0003).

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:71

Enthalten in:

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 71(2020), 16 vom: 19. Nov., Seite 2199-2206

Sprache:

Englisch

Beteiligte Personen:

Zhang, John J Y [VerfasserIn]
Lee, Keng Siang [VerfasserIn]
Ang, Li Wei [VerfasserIn]
Leo, Yee Sin [VerfasserIn]
Young, Barnaby Edward [VerfasserIn]

Links:

Volltext

Themen:

Adrenal Cortex Hormones
COVID-19
Coronavirus
Journal Article
Meta-Analysis
O3J8G9O825
Research Support, Non-U.S. Gov't
Risk factor
Ritonavir
Severe
Systematic Review
Treatment

Anmerkungen:

Date Completed 04.12.2020

Date Revised 04.11.2023

published: Print

Citation Status MEDLINE

doi:

10.1093/cid/ciaa576

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM309902657